New combo therapy shows promise for Hard-to-Treat stomach cancer
NCT ID NCT04984733
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tested a two-step treatment for people with advanced stomach or esophageal cancer that has a specific genetic change (MGMT deficiency) and has not responded to standard chemotherapy. First, patients received a drug called temozolomide to prime the tumor, followed by the immunotherapy nivolumab. The goal was to see if this combination could shrink tumors or control the disease. The trial enrolled 13 adults and was completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF ESOPHAGUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Conditions
Explore the condition pages connected to this study.